Trisomy 21 as the sole acquired karyotypic abnormality in biphenotypic acute leukemia [2]

International Journal of Hematology

Volumn 85, Issue 3, 2007, Pages 270-272

  Oka, Satoko ^a   Yokote, Taiji ^a   Akioka, Toshikazu ^a   Hara, Satoshi ^a   Kobayashi, Kichinosuke ^a   Hirata, Yuji ^a   Hiraoka, Nobuya ^a   Tsuji, Motomu ^a   Hanafusa, Toshiaki ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; VINCRISTINE;

ACUTE LEUKEMIA; ADULT; CANCER CHEMOTHERAPY; CASE REPORT; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG MEGADOSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; KARYOTYPING; LABORATORY TEST; LETTER; MALE; MULTIPLE CYCLE TREATMENT; PHENOTYPE; REMISSION; TREATMENT RESPONSE; TRISOMY 21;

ACUTE DISEASE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOWN SYNDROME; DOXORUBICIN; HUMANS; LEUKEMIA; MALE; TREATMENT OUTCOME; VINCRISTINE;

EID: 34247621862     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06223     Document Type: Letter

References (11)

1. Kantarjian HM, Hirsch-Ginsberg C, Yee G, et al. Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy. Blood. 1990;76:808-813.
2. Bene MC, Bernier M, Casasnovas RO, et al, for the European Group for the Immunological Classification of Leukemias (EGIL). The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. Blood. 1998;92:596-599.
3. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998;16:3803-3809.
4. Smith LJ, Curtis JE, Messner HA, et al. Lineage infidelity in acute leukemia. Blood. 1983;61:1138-1145.
5. Greaves MF, Chan LC, Furley AJ, et al. Lineage promiscuity in hemopoietic differentiation and leukemia. Blood. 1986;67:1-11.
6. Mitelman F, ed. ISCN 1995: An International System for Human Cytogenetic Nomenclature 1995. Basel, Switzerland: S Karger; 1995.
7. Mitelman F, Heim S, Mandahl N. Trisomy 21 in neoplastic cells. Am J Med Genet. 1990;7(suppl):262-266.
8. Carpenter E, Valverde-Garduno V, Sternberg A, et al. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. Br J Haematol. 2005;128:548-551.
9. Raimondi SC, Pui CH, Head D, et al. Trisomy 21 as the sole acquired chromosomal abnormality in children with acute lymphoblastic leukemia. Leukemia. 1992;6:171-175.
10. Wan TS, Au WY, Chan JC, et al. Trisomy 21 as the sole acquired karyotypic abnormality in acute myeloid leukemia and myelodysplastic syndrome. Leuk Res. 1999;23:1079-1083.
11. Takagi K, Yoshida A, Kinoshita K, et al. Unrelated donor bone marrow transplantation for acute mixed lineage (myeloid and B-lymphoid lineage) leukemia in an adult with Down syndrome. Ann Hematol. 2003;82:236-240.